Plain-language overview
Musculoskeletal medicine includes problems involving joints, cartilage, tendons, ligaments, menisci, bone, and the intervertebral disc. These tissues and diseases are different enough that a treatment studied in one should not automatically be assumed to work in another.
Research involving mesenchymal stromal cells (MSCs) includes several very different products, including culture-expanded MSCs, stromal vascular fraction, bone-marrow aspirate concentrate, and proprietary cell products. Their composition, manufacturing, dose, and route can differ substantially.
Most MSC-based musculoskeletal uses remain investigational. Human studies contain encouraging signals, important negative results, and substantial uncertainty; evidence belongs to the exact product, condition, procedure, comparator, and follow-up that were actually studied.
Knee osteoarthritis
Knee osteoarthritis has the largest musculoskeletal MSC evidence base, but the results are inconsistent across products and study designs.
Some small studies have reported improvements in pain or function, while larger or better-controlled studies have not consistently confirmed benefit. In the ADIPOA2 trial, for example, the main responder outcome did not significantly favor autologous adipose-derived MSCs over placebo.
Changes on MRI or other imaging should not automatically be described as regeneration of normal hyaline cartilage. Pain, function, durability, safety, and structural findings need to be evaluated separately.
Figure 1 placeholder — Knee osteoarthritis
Hip osteoarthritis
Hip osteoarthritis has much less human evidence than knee osteoarthritis.
Because the hip differs anatomically and mechanically from the knee, results from knee studies should not simply be transferred to hip disease. Evidence remains investigational and comparatively sparse.
Figure 2 placeholder — Hip osteoarthritis
Cartilage defects
Focal cartilage defects are different from generalized osteoarthritis. Some studies have combined cells with microfracture, fibrin, matrices, or surgical implantation.
When several treatments are used together, improvement cannot automatically be attributed to the cells alone. Scaffold mechanics, marrow recruitment, surgery, and rehabilitation may all contribute.
A specific MSC product, CARTISTEM, has a product-specific South Korean authorization for a defined knee cartilage indication. That authorization should not be generalized to other products, injections, indications, or countries.
Figure 3 placeholder — Cartilage defects
Tendon injury
MSC-related tendon research has examined possible effects on inflammation, collagen organization, vascular responses, and healing.
Human studies remain small and use different cell products, tear types, doses, and procedures. Current evidence does not establish routine regeneration of a torn tendon by injection alone.
Figure 4 placeholder — Tendon injury
Ligament injury
Direct human evidence that MSCs regenerate a torn ligament remains preclinical or very early.
Some research has examined cells as an adjunct after ligament reconstruction or in animal scaffold models. Those studies should not be described as proof that an MSC injection can reconstruct an untreated torn ligament.
Figure 5 placeholder — Ligament injury
Rotator-cuff disease
Rotator-cuff studies include small controlled and dose-escalation trials of cell injections or augmentation strategies.
Because the studies differ in product, tear type, control group, and delivery method, they do not establish a routine standard-care conclusion. Established orthopedic evaluation and treatment remain important.
Figure 6 placeholder — Rotator-cuff disease
Meniscal injury
One randomized study after partial medial meniscectomy reported limited MRI and subgroup pain signals after allogeneic bone-marrow MSC injection.
That result does not establish benefit for all traumatic or degenerative meniscal tears and should not be generalized beyond the studied post-meniscectomy setting.
Figure 7 placeholder — Meniscal injury
Bone defects
Cells used in bone-defect research may provide osteogenic activity or supportive signaling, but bone healing depends heavily on mechanical stability, blood supply, defect size, infection control, graft material, and surgical technique.
Studies frequently combine cells with scaffolds, grafts, fixation, or other procedures, making it difficult to determine how much of the outcome is caused by the cells themselves.
Figure 8 placeholder — Bone defects
Nonunion
Nonunion and delayed-union studies have reported feasibility and healing in small cohorts, but many combine cells with fixation, surgery, platelet-rich plasma, bone matrix, bioceramics, or allogeneic bone scaffold.
A randomized phase IIa pseudoarthrosis study supported feasibility more clearly than superiority over iliac-crest autograft. Current evidence remains investigational.
Figure 9 placeholder — Nonunion
Intervertebral-disc disease
Intradiscal MSC or mesenchymal-precursor-cell studies have reported some responder signals, but larger programs have also produced negative or inconclusive primary efficacy results.
The disc is a difficult biological environment because it is relatively hypoxic, acidic, and nutrient-poor. The relationship between imaging changes and pain is also uncertain.
Intradiscal injection has procedure-specific risks, including infection, and the evidence does not establish one optimal product, dose, carrier, or retreatment schedule.
Figure 10 placeholder — Intervertebral-disc disease
Why products called MSCs differ
In the approved evidence base, paracrine signaling and immunomodulation are proposed ways MSCs may influence surrounding tissue without becoming permanent replacement cells. The extracellular matrix is the structural environment around cells. A cartilage cell is a chondrocyte, a tendon cell is a tenocyte, a bone-forming cell is an osteoblast, and the central tissue of the intervertebral disc is the nucleus pulposus. Proposed osteoarthritis mechanisms include changes in synovial inflammation, while rotator-cuff research may examine tendon-to-bone healing.
Stromal vascular fraction is a heterogeneous mixture of stromal, vascular, immune, and other cells. Bone-marrow aspirate concentrate also contains many marrow-derived components and relatively few MSCs.
Culture-expanded MSCs are more selected cell populations, but their source, donor, passage, culture conditions, cryopreservation, viability, and potency can still differ. Evidence from one preparation should not be transferred automatically to another.
Dose, route, and procedure matter
Musculoskeletal studies have used intra-articular administration, intratendinous delivery, intradiscal injection, intraosseous delivery, scaffolds, and surgical implantation.
These routes have different retention, mechanical, procedural, and safety considerations. No universal MSC dose, interval, number of treatments, or rehabilitation program has been established across musculoskeletal conditions.
Safety and standard care
Temporary local pain, swelling, or arthralgia have been more common than serious treatment-attributed toxicity in the small trials reviewed, but existing sample sizes and follow-up cannot exclude uncommon or delayed harms.
Standard-care alternatives depend on the diagnosis and may include education, activity modification, weight management, physical therapy, medications, selected injections, repair or reconstruction, fixation, bone grafting, osteotomy, or arthroplasty.
Questions patients should ask
What exact diagnosis is being treated? What exact cell product was studied? Is it autologous or allogeneic? Is it culture-expanded MSCs, stromal vascular fraction, bone-marrow aspirate concentrate, or another product? What dose and route were tested? Was treatment combined with surgery, a scaffold, microfracture, or rehabilitation? What did the controlled human studies show for pain and function, not only imaging? What standard treatments are available?
Bottom line
Musculoskeletal MSC research should be interpreted condition by condition and product by product.
Knee osteoarthritis and intradiscal therapy have progressed further into randomized human research, but results remain mixed. Cartilage, tendon, ligament, meniscal, bone-defect, nonunion, and other applications are limited by small studies, heterogeneous products, or multicomponent procedures.
A plausible biological mechanism is a reason to perform good clinical trials—not proof that a treatment regenerates tissue or improves patient outcomes.
How this review was prepared
This Patient Edition was derived directly from the explicitly approved 0802 Professional Edition and preserves all ten controlling musculoskeletal Points and its condition-specific evidence framing.